Quality by design approach for the separation of naproxcinod and its related substances by fused core particle technology column.
This paper describes the development of a rapid, novel, stability-indicating gradient reversed-phase high-performance liquid chromatographic method and associated system suitability parameters for the analysis of naproxcinod in the presence of its related substances and degradents using a quality-by-design approach. All of the factors that affect the separation of naproxcinod and its impurities and their mutual interactions were investigated and robustness of the method was ensured. The method was developed using an Ascentis Express C8 150 × 4.6 mm, 2.7 µm column with a mobile phase containing a gradient mixture of two solvents. The eluted compounds were monitored at 230 nm, the run time was 20 min within which naproxcinod and its eight impurities were satisfactorily separated. Naproxcinod was subjected to the stress conditions of oxidative, acid, base, hydrolytic, thermal and photolytic degradation. Naproxcinod was found to degrade significantly in acidic and basic conditions and to be stable in thermal, photolytic, oxidative and aqueous degradation conditions. The degradation products were satisfactorily resolved from the primary peak and its impurities, proving the stability-indicating power of the method. The developed method was validated as per International Conference on Harmonization guidelines with respect to specificity, linearity, limit of detection, limit of quantification, accuracy, precision and robustness.
Dr. Reddy's Laboratories Ltd. Active Pharmaceutical Ingredients, IPDO, Bachupally, Hyderabad-500090, A.P, India. ugandharri@drreddys.com
Ugandar Reddy
UR
Inugala
Nageswara Rao
NR
Pothuraju
Ranga Reddy
RR
Vangala
D002851:Chromatography, High Pressure Liquid / Q000295:instrumentation / Q000379:methods*; D056148:Chromatography, Reverse-Phase / Q000295:instrumentation / Q000379:methods*; D004340:Drug Contamination; D009288:Naproxen / Q000031:analogs & derivatives* / Q000032:analysis / Q000302:isolation & purification; D012680:Sensitivity and Specificity
C111751:naproxen-n-butyl nitrate; D009288:Naproxen